12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks

NCT02303626 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Angioedema
HAE

Interventions

DRUG: BCX4161
DRUG: Placebo

Sponsor

BioCryst Pharmaceuticals